Overexcitability

Guster to Perform with Howard County Youth Orchestra at Merriweather Post Pavilion on May 21, 2023

Retrieved on: 
Wednesday, March 15, 2023
EPIC, Sale, Youth engagement, Howard County Public School System, YEP, Work, Ecosystem, Partnership, HCPSS, Merriweather Post Pavilion, Boston Pops Orchestra, Mid-Atlantic (United States), Organization, Culture, SAN, EST, Student, Intellectual giftedness, Parent, Do You Love Me, Pops, The arts, Merriweather, Culture Commission, Nightclub, Music, Tourism, Overexcitability, Satellite

COLUMBIA, Md., March 15, 2023 /PRNewswire/ -- The Downtown Columbia Arts and Culture Commission (DCACC) is excited to announce that iconic alternative-rock band Guster will be performing alongside the Howard County Youth Orchestra at Merriweather Post Pavilion on May 21.

Key Points: 
  • COLUMBIA, Md., March 15, 2023 /PRNewswire/ -- The Downtown Columbia Arts and Culture Commission (DCACC) is excited to announce that iconic alternative-rock band Guster will be performing alongside the Howard County Youth Orchestra at Merriweather Post Pavilion on May 21.
  • The Howard County Youth Orchestra is composed of high school students ranging from ages 14 to 18 who perform as part of the Howard County Public School System's Gifted and Talented Orchestra program, which has been recognized as one of the premier youth orchestras in the Mid-Atlantic region.
  • We are proud of our students and look forward to this groundbreaking opportunity to collaborate with Guster at the legendary Merriweather Post Pavilion.
  • "The partnership of Guster and the Howard County Youth Orchestra is a manifestation of the community engagement we strive for in Howard County, and what makes us the best place to live, work, play, and grow for all."

Impact of Key Alzheimer's Protein Depends on Type of Brain Cell in Which It Is Produced

Retrieved on: 
Tuesday, February 21, 2023
Brain, Overexcitability, Mouse, Development of the human body, Neuron, Hippocampus, Neurology, Patient, HIV disease progression rates, Cell, Research, Astrocyte, Risk, Pathology, Translation, Disease, SAN, Gladstone Institutes, University of California, San Francisco, UCSF, Doctor of Philosophy, Vaccine, Medical imaging, Apolipoprotein E, Alzheimer's disease, William Ewart Gladstone, MD

SAN FRANCISCO, Feb. 21, 2023 /PRNewswire/ -- Of all the known genetic risk factors for late-onset Alzheimer's disease, the strongest is a gene for the protein called ApoE4. People with one copy of this gene are 3.5 times more likely, on average, to develop Alzheimer's than others, and those with two copies face a 12-fold increased risk. However, exactly how ApoE4 boosts the risk of Alzheimer's remains unclear.

Key Points: 
  • Multiple types of cells in the brain make ApoE4—some of it is produced by neurons, but other brain cells called glia make it in higher quantities.
  • Now, researchers at Gladstone Institutes are shining a brighter spotlight on ApoE4 produced by neurons.
  • "Our findings suggest an opportunity to explore new treatments that would specifically target neuronal ApoE4 to protect against Alzheimer's disease."
  • Most ApoE in our brains is produced by a type of glial cell called astrocytes, and previous research suggested that astrocytic ApoE4 contributes to Alzheimer's disease.

Global Synchronous Condenser Market Trends/Analysis Report 2022: A $675+ Million Market by 2028 - Rising Conversion Of Prevailing Synchronous Generators Into Synchronous Condensers - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 27, 2022
Engineering, Other Manufacturing, Manufacturing, Overexcitability, Power, General Electric, Copper, International Renewable Energy Agency, ABB, Aluminium, Thermal conductivity, Motion control, TCP global synchronization, Ansaldo Energia, Risk, TGM, Statkraft, Growth, Acquisition, Climate, General of the branch, Grid, Electricity, Energy, Terna, Maintenance, WEG, Carbon, Engineering, Industrial, IRENA, Renewable energy, Electric motor, Electric power industry

The Global Synchronous Condenser Market size is expected to reach $676.9 Million by 2028, rising at a market growth of 2.9% CAGR during the forecast period.

Key Points: 
  • The Global Synchronous Condenser Market size is expected to reach $676.9 Million by 2028, rising at a market growth of 2.9% CAGR during the forecast period.
  • A synchronous condenser is a DC-excited synchronous machine (giant spinning generator) whose shaft is not connected to any driving equipment.
  • In 2021, the refurbished synchronous condenser segment garnered a significant revenue share of the synchronous condenser market.
  • In 2021, the hydrogen-cooled synchronous condenser segment acquired the highest revenue share of the synchronous condenser market.

Maintaining Balance in the Brain

Retrieved on: 
Tuesday, October 19, 2021
Gladstone Institutes, National, Neurology, Lists of diseases, Neuron, Cell Reports, Cell, Association, Technology, Media contacts database, Autism, Overexcitability, University of California, San Francisco, Epilepsy, Alzheimer's Association, Multimedia, Disease, SAN, Time, Brain, University, Learning, UC, Joseph, Ray, Communication, Metaphor, Student, Mobile phone, Medical imaging, Pharmaceutical industry

The situation is very similar in the brain, where cells must remain activebut in an orderly mannerto carry out their many important tasks.

Key Points: 
  • The situation is very similar in the brain, where cells must remain activebut in an orderly mannerto carry out their many important tasks.
  • So, inhibitory cells (the teachers) tamp down the excitation to maintain balance in the brain.
  • Our recent findings shed light onto how tau reduction affects different types of brain cells involved in creating abnormal network activity."
  • Together, these effects reduce the excitation-inhibition ratio in brain networks, counteracting diseases that cause abnormal increases in that ratio.

Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Retrieved on: 
Wednesday, September 29, 2021
Therapy, Clinical trial, Spasms, Neurodegeneration, Janssen Pharmaceuticals, Epilepsy, Achievement, PAM, Dyskinesia, SIX Swiss Exchange, Nasdaq, Patient, Glutamate (neurotransmitter), LR, American depositary receipt, Allosteric regulation, Overexcitability, Lists of diseases, NAM, Glutamic acid, Dystonia, Pain, Blepharospasm, Trial of the century, ADX71149, Â, Drug discovery, PTSD, Safety, Glutamate receptor, GABAB, Protein, L-DOPA, Pharmaceutical industry

Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) to downregulate neurotransmission through allosteric modulation.

Key Points: 
  • Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) to downregulate neurotransmission through allosteric modulation.
  • This double-blind, randomized Phase 2a feasibility study will enroll 15 patients with blepharospasm.
  • This study in blepharospasm is the third clinical study we have started this year, a significant achievement, particularly during these challenging times, said Tim Dyer, Chief Executive Officer of Addex.
  • Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID), in addition to the Phase 2 clinical study for blepharospasm.